The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has reviewed GE Healthcare’s Web site for its contrast agent, Visipaque (iodixanol) Injection, and deemed the promotional material “misleading because it presents unsubstantiated comparative claims and omits and minimizes the risks associated with Visipaque.” Therefore, the agency sent a letter to GE, stating that it [...]
Exploiting the Business Internet
Steven S Reeves
We’ll Send You Updates
